ClinicalTrials.gg
Not yet recruitingNCT07892625Updated Oct 23, 2026

A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC

A Phase 1 interventional study of HS-20093 for Injection and ZG006 in Extensive Stage Small Cell Lung Cancer (ES-SCLC), sponsored by Hansoh BioMedical R&D Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Updated Oct 23, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
338
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage small cell lung cancer.

Read the detailed description

This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage small cell lung cancer.

The study involves two cohorts, Cohort 1: HS-20093 in combination with ZG006; Cohort 2: HS-20093 in combination with ZG006 and adebrelimab. Each cohort contains two dosing regimens: every two weeks (Q2W) and every three weeks (Q3W). Two phases are included in each cohort: dose exploration phase and dose expansion phase.

02

Conditions studied

  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Keywords

  • Small Cell Lung Cancer
  • HS-20093
  • B7H3
  • Antibody-Drug Conjugates
  • ZG006
  • DLL3
  • PD-L1 inhibitor
03

In context

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

This study's planned enrollment of 338 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.

Browse Small Cell Lung Carcinoma studies →

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written .
  2. Men or women aged more than or equal to (≥) 18 years.
  3. At least one extra-cranial according to 1.1.
  4. or cytologically diagnosed as ES-SCLC.
  5. Adequate organ function.
  6. (ECOG) Performance Status of 0\~1.
  7. >= 12 weeks.
  8. Men or women should be using adequate measures throughout the study.
  9. Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled pleural effusion or peritoneal effusion.
  2. Adverse reactions caused by previous treatments.
  3. History of other primary solid tumors.
  4. Severe, uncontrolled or active cardiovascular or cerebrovascular diseases.
  5. Severe or uncontrolled diabetes or hypertension.
  6. hemorrhage symptoms or significant hemorrhagic tendency.
  7. History of severe arterial-venous thrombosis within 3 months prior to the first administration.
  8. History of severe infection within 4 weeks prior to the first administration.
  9. Active diseases or active infectious diseases.
  10. History of severe neurological or mental disorders.
  11. Hepatic encephalopathy, hepatorenal syndrome, or ≥ class B cirrhosis.
  12. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  13. Any condition that probably endangers the safety of the participants or interferes with the study assessment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
338 participants (estimated)

Study arms

  • Experimental
    Cohort 1a

    HS-20093 in combination with ZG006

    Drug: HS-20093 for Injection · Drug: ZG006

  • Experimental
    Cohort 1b

    HS-20093 in combination with ZG006

    Drug: HS-20093 for Injection · Drug: ZG006

  • Experimental
    Cohort 2a

    HS-20093 in combination with ZG006 and adebrelimab

    Drug: HS-20093 for Injection · Drug: ZG006 · Drug: Adebrelimab Injection

  • Experimental
    Cohort 2b

    HS-20093 in combination with ZG006 and adebrelimab

    Drug: HS-20093 for Injection · Drug: ZG006 · Drug: Adebrelimab Injection

Interventions

  • The patient will be treated with HS-20093.

    Also known as: Risvutatug Rezetecan, Ris-Rez, GSK5764227

  • DrugZG006

    The patient will be treated with ZG006.

  • The patient will be treated with adebrelimab.

06

What researchers measure

Primary outcomes

  1. The maximum tolerated dose (MTD) or maximum applicable dose (MAD) for combination treatments

    To determine the MTD or MAD for further evaluation of HS-20093 with other anti-cancer agents in subjects with Extensive Stage Small Cell Lung Cancer

    Time frame: Up to day 21 or 28 from the first dose

  2. The incidence rate of dose-limiting toxicities (DLT) events in combination treatments

    To determine the incidence rate of DLT events for further evaluation of HS-20093 with other anti-cancer agents in subjects with Extensive Stage Small Cell Lung Cancer

    Time frame: Up to day 21 or 28 from the first dose

Secondary outcomes

  1. Objective response rate (ORR) determined by investigators

    ORR is defined as the percentage of patients with a CR or PR that is confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1

    Time frame: up to approximately 24 months

  2. Disease control rate (DCR) determined by investigators

    Disease control is defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 5 weeks).

    Time frame: up to approximately 24 months

  3. Duration of response (DoR) determined by investigators

    The duration of remission (DoR) is defined as the time period between the date of the first occurrence of remission and the date of the first disease progression or any cause of death.

    Time frame: up to approximately 24 months

  4. Progression-free survival (PFS) determined by investigators according to RECIST 1.1

    PFS is defined as the time from first dose until PD or death from any cause (whichever occurred first).

    Time frame: up to approximately 24 months

  5. Overall survival (OS)

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: Up to approximately 24 months.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 22 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2026
First posted
Oct 23, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Sep 15, 2028
CompletionEst.
Sep 15, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07892625
Responsible party
Sponsor
First posted
Oct 23, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Sep 15, 2028 (estimated)
Completion
Sep 15, 2029 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risvutatug rezetecan · Alveltamig

Start the discussion